Published in Women's Health Weekly, June 23rd, 2005
The multicenter study was randomized, double-blind, placebo-controlled, and designed to investigate the efficacy and safety of three strengths of the Femprox cream in premenopausal and post-menopausal women diagnosed with female sexual arousal disorder (FSAD).
Femprox is applied topically and incorporates alprostadil, a vasodilator, with the NexACT permeation technology. The results were announced at the annual meeting of the American Urological Association.
The patients, who were between the ages of 21 and 65, were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly